Brokers Set Expectations for Humacyte FY2025 Earnings

Humacyte, Inc. (NASDAQ:HUMA) – Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Humacyte in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings of ($0.95) per share for the year. The consensus estimate for Humacyte’s current full-year earnings is ($1.27) per share.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.08). During the same quarter last year, the firm posted ($0.25) EPS.

HUMA has been the subject of several other reports. Benchmark raised their price target on shares of Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, December 23rd. BTIG Research reiterated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price (up previously from $12.00) on shares of Humacyte in a research report on Friday, December 20th. D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research report on Tuesday. Finally, Piper Sandler set a $6.00 target price on shares of Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Humacyte has a consensus rating of “Buy” and an average price target of $13.71.

Humacyte Trading Up 0.7 %

Humacyte stock opened at $4.59 on Thursday. The firm has a 50 day simple moving average of $4.52 and a 200 day simple moving average of $5.64. Humacyte has a 1-year low of $2.80 and a 1-year high of $9.97. The firm has a market capitalization of $577.70 million, a price-to-earnings ratio of -3.43 and a beta of 1.32.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HUMA. Rhumbline Advisers increased its holdings in Humacyte by 87.8% during the second quarter. Rhumbline Advisers now owns 110,919 shares of the company’s stock valued at $532,000 after buying an additional 51,858 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after buying an additional 524,600 shares during the last quarter. XTX Topco Ltd purchased a new stake in Humacyte during the second quarter valued at approximately $110,000. Profund Advisors LLC purchased a new stake in Humacyte during the second quarter valued at approximately $97,000. Finally, Bank of Montreal Can purchased a new stake in Humacyte during the second quarter valued at approximately $495,000. Institutional investors own 44.71% of the company’s stock.

Insider Buying and Selling

In other news, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Laura E. Niklason sold 811,172 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.44, for a total transaction of $3,601,603.68. Following the completion of the transaction, the chief executive officer now owns 2,419,712 shares in the company, valued at approximately $10,743,521.28. This represents a 25.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,500,000 shares of company stock valued at $6,606,799 over the last quarter. Corporate insiders own 11.20% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.